

Chemoprophylaxis for HIV Prevention in Peruvian Men

Project Staff: Gladstone Institute of Virology and Immunology: Robert Grant, Vivian Levy, Jeff McConnell, Vanessa McMahan;
UCSF: Kimberly Page-Shafer, David Glidden;
IMPACTA: Javier Lama, Pedro Goicochea, Juan Guanira, Lorena Vargas, Rosario Leon, Juan Carlos Hinojosa Boyer, Lucia Ruiz, Graciela Meza

Project Description: Novel approaches to HIV-1 prevention warrant urgent evaluation. Tenofovir disoproxil fumarate (tenofovir or TDF), a nucleotide reverse transcriptase inhibitor, has been demonstrated to prevent transmission of simian immunodeficiency virus (SIV) when administered near the time of virus challenge. The efficacy of tenofovir chemoprophylaxis for HIV-1 prevention in people is not known. The primary goal of this proposal is to conduct a randomized blinded clinical trial evaluating the safety and efficacy of chemoprophylactic therapy using once daily tenofovir 300 mg to prevent HIV-1 acquisition in high-risk uninfected men who have sex with men (MSM).

Significance: Pre-exposure prophylaxis, or PrEP, is one of several experimental prevention interventions (including microbicides and vaccines) which could potentially provide additional modes of minimizing the risk of HIV infection.

Project End Date: August 2009